TY - JOUR
T1 - Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines
AU - Lustig, Yaniv
AU - Barda, Noam
AU - Weiss-Ottolenghi, Yael
AU - Indenbaum, Victoria
AU - Margalit, Ili
AU - Asraf, Keren
AU - Doolman, Ram
AU - Chalkias, Spyros
AU - Das, Rituparna
AU - Elfatarany, Gamal
AU - Harats, Dror
AU - Kreiss, Yitshak
AU - Regev-Yochay, Gili
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024
Y1 - 2024
N2 - JN.1, the dominating SARS-CoV-2 variant, is antigenically distinct from ancestral BA.1, BA.5 and XBB.1.5 variants, raising concern about effectiveness of updated COVID-19 vaccines. Here, we compared the neutralizing antibody response against JN.1, 1-month after receipt of the three available Moderna mRNA vaccines. Sera obtained from 37, 30 and 30 XBB.1.5, BA.1 and BA.4-5 -vaccine recipients, respectively, were tested for anti-RBD IgG and for JN-1 specific neutralizing antibody levels. Geometric mean fold rise (GMFR) in JN.1 specific neutralizing titers was 27 (95 % CI: 17–43.1), 10.1 (95 % CI: 6.48–15.7) and 8.77 (95 % CI: 5.69–13.5) following XBB.1.5, BA.1 and BA.4-5 vaccines, respectively, translating into a 64 % lower adjusted response (geometric mean ratio [GMR] = 0.36, 95 % CI: 0.21–0.6) in the BA.1 arm, and a 75 % lower response (GMR = 0.25, 95 % CI: 0.15–0.43) in the BA.4-5 arm. This suggests that XBB.1.5 vaccination will most likely, result in improved effectiveness against JN.1 compared with other COVID-19 vaccines.
AB - JN.1, the dominating SARS-CoV-2 variant, is antigenically distinct from ancestral BA.1, BA.5 and XBB.1.5 variants, raising concern about effectiveness of updated COVID-19 vaccines. Here, we compared the neutralizing antibody response against JN.1, 1-month after receipt of the three available Moderna mRNA vaccines. Sera obtained from 37, 30 and 30 XBB.1.5, BA.1 and BA.4-5 -vaccine recipients, respectively, were tested for anti-RBD IgG and for JN-1 specific neutralizing antibody levels. Geometric mean fold rise (GMFR) in JN.1 specific neutralizing titers was 27 (95 % CI: 17–43.1), 10.1 (95 % CI: 6.48–15.7) and 8.77 (95 % CI: 5.69–13.5) following XBB.1.5, BA.1 and BA.4-5 vaccines, respectively, translating into a 64 % lower adjusted response (geometric mean ratio [GMR] = 0.36, 95 % CI: 0.21–0.6) in the BA.1 arm, and a 75 % lower response (GMR = 0.25, 95 % CI: 0.15–0.43) in the BA.4-5 arm. This suggests that XBB.1.5 vaccination will most likely, result in improved effectiveness against JN.1 compared with other COVID-19 vaccines.
KW - COVID-19 vaccination
KW - JN.1 variant
KW - Neutralizing antibodies
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85194317910&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2024.05.058
DO - 10.1016/j.vaccine.2024.05.058
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38806352
AN - SCOPUS:85194317910
SN - 0264-410X
VL - 42
JO - Vaccine
JF - Vaccine
IS - 22
M1 - 126010
ER -